References
1. Park PG, Hong CR, Kang E, et al. Acute kidney injury in pediatric
cancer patients. J Pediatr 2019;208:243–250.
2. Luciano RL, Brewster UC. Kidney involvement in leukemia and lymphoma.
Adv Chronic Kidney Dis 2014;21:27–35.
3. Bharat A, Mehta A, Tiwari HC, Sharma B, Singh A, Singh V. Spectrum
and immediate outcome of acute kidney injury in a pediatric intensive
care unit: a Snapshot Study from Indian Subcontinent. Indian J Crit Care
Med 2019;23:352–355.
4. Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL. Epidemiology of acute
kidney injury in critically ill children and young adults. N Engl J Med
2017;376:11–20.
5. Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood
2012;119:5980–5988.
6. Parkin DM, Stiller CA, Draper GJ, Bieber CA. The international
incidence of childhood cancer. Int J Cancer 1988;42:511–520.
7. Demanelis K, Sriplung H, Meza R, et al. Differences in childhood
leukemia incidence and survival between Southern Thailand and the United
States: a population-based analysis. Pediatr Blood Cancer
2015;62:1790–1798.
8. Rasche M, Zimmermann M, Borschel L, et al. Successes and challenges
in the treatment of pediatric acute myeloid leukemia: a retrospective
analysis of the AML-BFM trials from 1987 to 2012. Leukemia
2018;32:2167–2177.
9. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed
therapy for childhood acute myeloid leukaemia: results of the AML02
multicentre trial. Lancet Oncol 2010;11:543–552.
10. Du Plessis L, Rassekh SR, Mammen C. High incidence of acute kidney
injury during chemotherapy for childhood acute myeloid leukemia. Pediatr
Blood Cancer 2018;65:e26915.
11. Creutzig U, Ritter J, Schellong G. Identification of two risk groups
in childhood acute myelogenous leukemia after therapy intensification in
study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group.
Blood 1990;75:1932–1940.
12. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by
optimizing chemotherapy, but not by addition of granulocyte
colony-stimulating factor in children and adolescents with acute myeloid
leukemia: results of AML-BFM 98. J Clin Oncol 2006;24:4499–4506.
13. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of
the safety of gemtuzumab ozogamicin in combination with chemotherapy for
newly diagnosed childhood acute myeloid leukemia: a report from the
Children’s Oncology Group. Cancer 2012;118:761–769.
14. Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: Improving
global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical
practice guideline for acute kidney injury. Kidney Int Suppl
2012;2:1–138.
15. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine
concentration for estimating glomerular filtration rate in infants,
children, and adolescents. Pediatr Clin North Am 1987;34:571–590.
16. Schwartz GJ, Work DF. Measurement and estimation of GFR in children
and adolescents. Clin J Am Soc Nephrol 2009;4:1832–1843.
17. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic
strategies and classification. Br J Haematol 2004;127:3–11.
18. Goldstein B, Giroir B, Randolph A, International Consensus
Conference on Pediatric Sepsis. International pediatric sepsis consensus
conference: definitions for sepsis and organ dysfunction in pediatrics.
Pediatr Crit Care Med 2005;6:2–8.
19. Fisher BT, Zaoutis TE, Leckerman KH, Localio R, Aplenc R. Risk
factors for renal failure in pediatric patients with acute myeloid
leukemia: a retrospective cohort study. Pediatr Blood Cancer
2010;55:655–661.
20. Lahoti A, Kantarjian H, Salahudeen AK, et al. Predictors and outcome
of acute kidney injury in patients with acute myelogenous leukemia or
high-risk myelodysplastic syndrome. Cancer 2010;116:4063–4068.
21. Ballo O, Eladly F, Büttner S, et al. Acute kidney injury adversely
affects the clinical course of acute myeloid leukemia patients
undergoing induction chemotherapy. Ann Hematol 2021;100:1159–1167.
22. Creutzig U, Büchner T, Sauerland MC, et al. Significance of age in
acute myeloid leukemia patients younger than 30 years. Cancer
2008;112:562–571.
23. Rubnitz JE, Pounds S, Cao X, et al. Treatment outcome in older
patients with childhood acute myeloid leukemia. Cancer
2012;118:6253–6259.
24. Dix D, Cellot S, Price V, et al. Association between corticosteroids
and infection, sepsis, and infectious death in pediatric acute myeloid
leukemia (AML): results from the Canadian Infections in AML Research
Group. Clin Infect Dis 2012;55:1608–1614.
25. Riley LC, Hann IM, Wheatley K, Stevens RF. Treatment-related deaths
during induction and first remission of acute myeloid leukaemia in
children treated on the Tenth Medical Research Council acute myeloid
leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party.
Br J Haematol 1999;106:436–444.
26. Vachvanichsanong P, Dissaneewate P, Lim A, McNeil E. Childhood acute
renal failure: 22-year experience in a university hospital in Southern
Thailand. Pediatrics 2006;118:e786–791.
TABLE 1 Comparison of demographic characteristics by
development of AKI
TABLE 2 Logistic regression results for identifying factors
associated with AKI in childhood AML patients
TABLE 3 Comparison of treatment outcomes by development of AKI
FIGURE 1 Median (interquartile range) of maximum creatinine
levels in 56 childhood AML patients with AKI stratified by AKI severity
and age at diagnosis
FIGURE 2 Kaplan-Meier survival curve of the 112 study patients
with AML stratified by development of AKI